The news report: Thursday, April 9, 2009

Posted on April 9, 2009 by Sitemaster

Today’s news reports address: The association between metabolic syndrome and prostate cancer The association between health habits (smoking, drinking, and exercise) and prostate cancer risk The use of MRI to project risk of disease recurrence post-surgery Another possible long-term drug development lead

Filed under: Drugs in development, Living with Prostate Cancer, Management, Prevention, Risk | Tagged: , , , , , , | Leave a Comment »

A respected voice emphasizes the need for change

Posted on April 8, 2009 by Sitemaster

In a state-of-the-art lecture delivered at the ongoing World Robotic Urology Symposium earlier today, Dr. Peter Scardino, the Chairman of the Department of Surgery at Memorial Sloan-Kettering Cancer Center, apparently added his voice to some significant calls for reassessment of the way early stage prostate cancer is currently managed in the USA.

Filed under: Diagnosis, Management, Risk, Treatment | Tagged: , , | 1 Comment »

The news report: Wednesday, April 8, 2009

Posted on April 8, 2009 by Sitemaster

Today’s news report addresses such issues as: Prostate cancer screening in organ transplant patients Circulating tumor cell gene analysis and late stage disease Exercise therapy and prostate cancer Penile rehabilitation post-surgery Possible new drugs and drug targets

Filed under: Diagnosis, Drugs in development, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: , , , , , , | Leave a Comment »

An MDV3100 update

Posted on April 7, 2009 by Sitemaster

There are several stories on the Web today about a forthcoming article in Science giving data about a phase I/II trial of MDV3100.

Filed under: Drugs in development, Management, Treatment | Tagged: | Leave a Comment »

Dana Jennings on faith

Posted on April 7, 2009 by Sitemaster

In his article this week (“In cancer, a deeper faith“) Dana writes about how his faith affects his personal journey.

Filed under: Uncategorized | Comments Off

More on the surgical learning curve for LRP

Posted on April 7, 2009 by Sitemaster

A study to appear in Lancet Oncology has reported information on the surgical learning curve associated with (non-robotic) laparoscopic radical prostatectomy (LRP). The study appears to confirm prior reports that LRP is a difficult technique to learn to do well.

Filed under: Management, Treatment | Tagged: , , | 2 Comments »

Stress management and prostate cancer surgery

Posted on April 7, 2009 by Sitemaster

An upcoming article in the Journal of Clinical Oncology apparently indicates that stress management prior to radical prostatectomy (RP) can significantly impact patients’ responses to treatment in both the short and the long term. Specifically, the study showed that men who participated in brief stress management sessions experienced less short-term mood disturbance and better long-term [...]

Filed under: Management, Treatment | Tagged: | Leave a Comment »

The news report: Tuesday, April 7, 2009

Posted on April 7, 2009 by Sitemaster

Today’s news report covers articles on: Prevention of prostate cancer and other prostate disorders Pelvic lymph node dissection Sexual activity at 15 years after radiation therapy Non-hormonal, non-surgical orchiectomy Another possible prostate cancer drug

Filed under: Drugs in development, Living with Prostate Cancer, Management, Prevention, Treatment | Tagged: , , , , , , | Leave a Comment »

Prostate cancer: weighing options

Posted on April 7, 2009 by Sitemaster

The second part of Melinda Beck’s two-part article on prostate cancer has just been published in the Wall Street Journal today, with the above title. For those who missed the first part, see “The man, the gland, the dilemmas.”

Filed under: Uncategorized | Comments Off

From the “Why are we hearing about this now?” desk

Posted on April 6, 2009 by Sitemaster

A media release hyping a new report from the market research firm Decision Resources states that “surveyed oncologists identify a therapy’s effect on overall survival as the attribute that most influences their prescribing decisions in stage III prostate cancer” and goes on to say that “the opinions of interviewed thought leaders indicate that Sanofi-Aventis’s Taxotere [...]

Filed under: Drugs in development, Management, Treatment | Tagged: , | 1 Comment »

Eight US-based advocacy groups issue joint policy agenda

Posted on April 6, 2009 by Sitemaster

Prostate Cancer International, the parent of The “New” Prostate Cancer InfoLink, is one of eight, US-based, prostate cancer advocacy organizations that issued the following media release about a joint policy agenda this morning.

Filed under: Uncategorized | Tagged: , | Leave a Comment »

“Remark all … warts:” An entirely personal opinion about risk and prostate cancer

Posted on April 5, 2009 by Sitemaster

Over the past two weeks, I have read, watched, or listened to nearly every piece I could find on reactions to the two screening articles that appeared in the New England Journal of Medicine. I have also watched, monitored, and participated in  many resulting discussions within and outside the prostate cancer community. As a consequence, [...]

Filed under: Diagnosis, Living with Prostate Cancer, Risk | Tagged: , , , , | 32 Comments »

Of LUTS, ED, and “changing clinical practice”

Posted on April 5, 2009 by Sitemaster

A review article published last September on the relationship between erectile dysfunction (ED) and lower urinary tract symptoms (LUTS) has just been defined by Faculty of 1000 Medicine as “changing clinical practice.”

Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: , , | Leave a Comment »

Your weekend news reports: April 4, 2009

Posted on April 4, 2009 by Sitemaster

The three reports in today’s news cover: A future perspective on treatments for localized disease Robot-assisted laparoscopic prostatectomy in Europe Long-term follow-up on urinary toxicities following brachytherapy

Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: , , , , , , | 1 Comment »

The full Provenge saga

Posted on April 3, 2009 by Sitemaster

For those who have come to the world of prostate cancer in the past 2 years or so, we recommend that, before you attempt to understand whatever happens on the day that Dendreon announces the results of the Phase III (IMPACT) trial of sipleucel-T, a.k.a. Provenge (expected some time this month), you read the well-constructed [...]

Filed under: Drugs in development | Tagged: , | 2 Comments »

« Previous Page — Next Page »
Follow

Get every new post delivered to your Inbox.

Join 249 other followers